Previous Article | Next Article 
Journal of Virology, June 2006, p. 5509-5515, Vol. 80, No. 11
0022-538X/06/$08.00+0 doi:10.1128/JVI.02659-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Diversity of the CD8+ T-Cell Response to Herpes Simplex Virus Type 2 Proteins among Persons with Genital Herpes
Nancy Hosken ,6,
,
Patrick McGowan,6,
,
Amalia Meier,1,5
David M. Koelle,1,2,3,4,7
Paul Sleath,6
Felecia Wagener,6
Mark Elliott,6
Ken Grabstein,6
Christine Posavad,2 and
Lawrence Corey1,2,4*
Departments of Laboratory Medicine,1
Medicine,2
Pathobiology, University of Washington, Seattle, Washington,3
Program in Infectious Diseases,4
Biostatistics, Fred Hutchinson Cancer Research Center, Seattle, Washington,5
Corixa Corporation, Seattle Washington,6
Benaroya Research Institute, Seattle, Washington7
Received 19 December 2005/
Accepted 17 March 2006
Cytolytic T cells play a major role in controlling herpes simplex virus type 2 (HSV-2) infections in humans. In an effort to more thoroughly evaluate the response to HSV-2 directly, ex vivo, we developed an enzyme-linked immunospot (ELISPOT) assay that utilized pools of overlapping synthetic peptides presented by autologous dendritic cells to purified CD8+ T cells. Donor response rates to individual open reading frames (ORFs) ranged from fewer than 5% responding to as many as 70% responding, with the greatest frequency of responses (by ORF) being directed against UL39, UL25, UL27, ICP0, UL46, and UL47 in descending order of frequency. HSV-2-seropositive subjects responded to as few as 3 or as many as 46 of the 48 ORFs tested, with a median of 11 ORFs recognized. HLA-B*07 expression correlated with stronger responses overall that were directed primarily against UL49 and UL46. Cumulative precursor frequencies in the blood ranged from 500 to almost 6,000 HSV-2 spot-forming units/106 CD8+ T cells. The magnitude and breadth of the response in the infected population were greater than previously appreciated. Whether this variability in the CD8+ T-cell response within individuals is associated with the frequency of viral reactivation warrants further study.
* Corresponding author. Mailing address: Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., LE-500, Seattle, WA 98109. Phone: (206) 667-6770. Fax: (206) 667-7711. E-mail:
lcorey{at}u.washington.edu.
Present address: ZymoGenetics Corporation, Seattle, Washington.
N.H. and P.M. contributed equally to the conception and conduct of this report.
Present address: Glaxo-Smithkline Biologicals Seattle, Seattle, Washington.
Journal of Virology, June 2006, p. 5509-5515, Vol. 80, No. 11
0022-538X/06/$08.00+0 doi:10.1128/JVI.02659-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Muller, W. J., Dong, L., Vilalta, A., Byrd, B., Wilhelm, K. M., McClurkan, C. L., Margalith, M., Liu, C., Kaslow, D., Sidney, J., Sette, A., Koelle, D. M.
(2009). Herpes simplex virus type 2 tegument proteins contain subdominant T-cell epitopes detectable in BALB/c mice after DNA immunization and infection. J. Gen. Virol.
90: 1153-1163
[Abstract]
[Full Text]
-
Bernstein, D. I., Cardin, R. D., Bravo, F. J., Strasser, J. E., Farley, N., Chalk, C., Lay, M., Fairman, J.
(2009). Potent Adjuvant Activity of Cationic Liposome-DNA Complexes for Genital Herpes Vaccines. CVI
16: 699-705
[Abstract]
[Full Text]
-
Cattamanchi, A., Posavad, C. M., Wald, A., Baine, Y., Moses, J., Higgins, T. J., Ginsberg, R., Ciccarelli, R., Corey, L., Koelle, D. M.
(2008). Phase I Study of a Herpes Simplex Virus Type 2 (HSV-2) DNA Vaccine Administered to Healthy, HSV-2-Seronegative Adults by a Needle-Free Injection System. CVI
15: 1638-1643
[Abstract]
[Full Text]
-
Kim, M., Taylor, J., Sidney, J., Mikloska, Z., Bodsworth, N., Lagios, K., Dunckley, H., Byth-Wilson, K., Denis, M., Finlayson, R., Khanna, R., Sette, A., Cunningham, A. L.
(2008). Immunodominant Epitopes in Herpes Simplex Virus Type 2 Glycoprotein D Are Recognized by CD4 Lymphocytes from Both HSV-1 and HSV-2 Seropositive Subjects. J. Immunol.
181: 6604-6615
[Abstract]
[Full Text]
-
Koelle, D. M., Magaret, A., McClurkan, C. L., Remington, M. L., Warren, T., Teofilovici, F., Wald, A.
(2008). Phase I Dose-Escalation Study of a Monovalent Heat Shock Protein 70-Herpes Simplex Virus Type 2 (HSV-2) Peptide-Based Vaccine Designed To Prime or Boost CD8 T-Cell Responses in HSV-Naive and HSV-2-Infected Subjects. CVI
15: 773-782
[Abstract]
[Full Text]
-
Milikan, J. C. M., Kinchington, P. R., Baarsma, G. S., Kuijpers, R. W. A. M., Osterhaus, A. D. M. E., Verjans, G. M. G. M.
(2007). Identification of Viral Antigens Recognized by Ocular Infiltrating T Cells from Patients with Varicella Zoster Virus-Induced Uveitis. IOVS
48: 3689-3697
[Abstract]
[Full Text]
-
Zhu, J., Koelle, D. M., Cao, J., Vazquez, J., Huang, M. L., Hladik, F., Wald, A., Corey, L.
(2007). Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. JEM
204: 595-603
[Abstract]
[Full Text]